Spanish personalized medicine company, inbiomotion, secures €2.2M from Caixa and Ysios

“la  Caixa”  has led  a 2.2  million  Euro  investment  round  in the  Inbiomotion  company.  The  investment  has  been made through   Caixa  Innvierte BioMed  II,  a  vehicle  managed  by  Caixa  Capital  Risc,  the   venture  capital  arm   of ”la Caixa”.   The   fund   is   driven   by  ”la   Caixa”   and   the   Centro   para   el   Desarrollo Tecnológico  Industrial  (Centre for Industrial  Technological  Development,  CDTI) under the  framework  of  the  Innvierte  Programme  and   has minority  participation  from  the Institut Català de Finances.

Also participating in the Inbiomotion operation are Ysios Capital, the leading Spanish venture capital for the  biotech sector, through  its Ysios BioFund I fund, and  Fundación Vila Casas, which were  already shareholders of the company.

Doctor Roger  Gomis, founder of Inbiomotion and  one  of the most renowned researchers in metastasis,  says: “We are  delighted to have  the  support of Caixa Capital Risc. This funding is a qualitative and  quantitative leap forward for us that will allow us to complete the clinical validation and put Inbiomotion’s first product  within the reach of patients”.

“We are  excited to work with the Inbiomotion team. The development of diagnostic tests for predicting the  risk that  cancer patients may  suffer from bone  metastasis will have  a great   impact  on  the  clinical  practices  for these patients”,  states Jose Antonio  Mesa, Director of Investments at Caixa Capital Risc.

Inbiomotion is a spin-off of the Institut de Recerca Biomèdica de Barcelona (Institute for Biomedical Research of Barcelona, IRB Barcelona), a centre associated with the Universitat    de    Barcelona,    and    the    Institució    Catalana    de    Recerca   i    Estudis Avançats (Institute  of Advanced Research  and  Studies  of Catalonia,  ICREA),  led  on  a scientific level by Roger  Gomis. Gomis is a researcher at ICREA, and  the research that has given  rise  to this  start-up has been funded, in  part,  by a grant  from the  ”la  Caixa” Foundation.

Inbiomotion  develops  diagnostic  tests for predicting  the  risk  that  cancer patients  may suffer bone  metastasis. Bone  metastasis occurs when  a tumour  growing in another part of the  patient’s body  spreads out through  the  bloodstream, overcomes all of the  body’s defences, and  colonises itself in the  bone. These metastatic cancers are  usually highly aggressive, painful, and ultimately result in the patient’s death.

The target  market  for Inbiomotion is patients with prostate or breast cancer, where  bone is  the  most common site  for metastasis.  Some 75%  of women  with  metastatic  breast cancer and  90% of men with metastatic prostate cancer develop bone  metastasis during the  course of their  disease.  This  will also  happen with  15-30%  of patients  with  other types of tumours, such as lung, colon, stomach, uterine, rectal, thyroid, or kidney.

Methods of diagnosis

Currently there  are no complementary treatments to chemotherapy to prevent bone metastasis   because  currently   there    is   no   diagnostic   tool   capable   of   specifically predicting   bone   metastasis.   A  product   like   the   one   from   Inbiomotion   would   help rationalise the  use of preventive therapies against metastasis, improve clinical practice, define  the  prognosis,  and  make  it possible  to apply  personalised  solutions  to patients, as well as make  better  use of health care  and drug resources.

Osteomet, the  product  developed  by Inbiomotion,  has already  been validated  in  over 1300 samples of patients from independent cohorts in multiple countries, and the company’s main objective is to finish its clinical and  regulatory development in the  next 2 years.

About Caixa Capital Risc

Caixa Capital Risc, the  venture capital arm  of ”la Caixa”, invests in the  early stages of innovative  SMEs. To facilitate  funding  for companies  in  the  start-up phase, ”la  Caixa” launched  a  set of specific  initiatives  and  financial  instruments  in  2004.  Caixa  Capital Risc currently manages 160 million Euros through  various specialised vehicles based on the  sector and  stage of growth  of the  project  and  has minority  participation  from  the CDTI,   the   ICO,   the   ICF,   and   other   agents.  Although   they   invest   in   multi-sector companies with a global vision, Caixa Capital Risc remains focused on sectors they consider to be emerging: technology, digital industries, industrial technology, and life sciences.

About Ysios Capital

Ysios Capital is a venture capital firm specialised in investments in companies in the life sciences   field,   particularly   in   biomedicine,   diagnostics,   and   medical   technologies. Founded in  2008,  Ysios  Capital  has 130  million  Euros under  management, distributed into  two  funds.  Its  second  fund,   Ysios  BioFund  II  Innvierte,  has  a  target   size  of

100 million Euros and is open  to new investors until March 2016.

About Inbiomotion

Inbiomotion  SL,  a  company  founded  by  Doctor  Roger   Gomis,  who  came from  the Cancer Metastasis and Growth Control group  of the Instituto de Investigación Biomédica (IRB Barcelona) and  ICREA, is dedicated to developing biomarkers for predicting bone metastasis using biopsies of primary tumours. In July 2012,  Inbiomotion concluded the first round  of investment from Ysios Capital for a total of 2 million Euros. Inbiomotion’s unique  biomarker  codifies  a  nuclear  protein  and  makes it  possible  to  predict  which patients  will  suffer  from  bone   disease.  The   biomarker  has  been validated  in  over 900 samples of patients from two independent cohorts through  three  independent techniques (gene expression,  IHC, and  ISH),  and  has resulted in a negative predictive value of over 95%.


Source: inbiomotion Press Release

Email this to someoneShare on LinkedInShare on FacebookTweet about this on TwitterShare on Google+